Stock News

3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector
UPDATE 2-Biogen scraps two late-stage trials for Alzheimer's treatment
Biogen's stock falls after co. and Eisai to discontinue late-stage trial of Alzheimer's treatment
Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years

As seen on...